Inclusion and exclusion criteria for specimens included:
Item
Inclusion and exclusion criteria for specimens included:
boolean
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
Item
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
boolean
C1512693 (UMLS CUI [1,1])
C2735298 (UMLS CUI [1,2])
C5206782 (UMLS CUI [1,3])
C4272796 (UMLS CUI [1,4])
C1521750 (UMLS CUI [1,5])
C0282564 (UMLS CUI [1,6])
C0604937 (UMLS CUI [1,7])
C0587348 (UMLS CUI [1,8])
C0470187 (UMLS CUI [1,9])
C2707520 (UMLS CUI [1,10])
C1442880 (UMLS CUI [1,11])
C0011900 (UMLS CUI [1,12])
C0035020 (UMLS CUI [1,13])
C3845275 (UMLS CUI [2,1])
C0150103 (UMLS CUI [2,2])
C5192904 (UMLS CUI [2,3])
C0001779 (UMLS CUI [2,4])
C0686906 (UMLS CUI [2,5])
C0018939 (UMLS CUI [2,6])
C5205410 (UMLS CUI [2,7])
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
Item
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
boolean
C0680251 (UMLS CUI [1,1])
C0023487 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0282564 (UMLS CUI [1,4])
C0604937 (UMLS CUI [1,5])
C0857127 (UMLS CUI [1,6])
C0205336 (UMLS CUI [2,1])
C3843629 (UMLS CUI [2,2])
C0332137 (UMLS CUI [2,3])